ReviewCurrent topics in medicinal chemistry2025
An Updated Review on Nipah Virus Infection with a Focus on Encephalitis, Vasculitis, and Therapeutic Approaches.
Review in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modulation of Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Gastrointestinal Cancers by Phytochemicals.Pharmaceutical research · 2026Review
- Exploring the Role of Cerebrospinal Fluid and Serum Mid-Regional Pro-Adrenomedullin in Tick-Borne Encephalitis: A Pilot Study.Diagnostics (Basel, Switzerland) · 2025Article
- Alternative medicines in oncology: a focus on natural products against gastric cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV), a member of the Paramyxoviridae family, has gained global attention owing to its high mortality rate and destructive potential. NiV has a Biosafety Level 4 (BSL-4) rating and has repeatedly precipitated devastating outbreaks associated with severe respiratory infections, often accompanied by encephalitis and systemic vasculitis. Several studies have been conducted to understand the mechanisms involved in its pathogenesis and to effectively produce new medications to treat this zoonotic virus. However, the cruelty of NiV and its propensity to elude existing treatments underscores the need to elucidate better therapeutics to manage NiV infection more effectively. Therefore, this review highlights the fundamental mechanisms involved in the etiology of NiV, specifically fatal encephalitis and systemic vasculitis. Furthermore, this study investigated promising therapeutic strategies to mitigate the clinical consequences of NiV infections.
Indexed as
Identifiers
40468923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.